Found 285 articles for: "biologics"
An Overview of Biologics for Psoriasis
November 2021 | Volume 20 | Issue 11 | Features | 1246 | Copyright © November 2021
The use of biologics has revolutionized the treatment of psoriasis but choosing the right agent could be challenging. Currently, there are multiple biologic options, each with advantages and disadvant...
Read MoreTreating Cutaneous Immune-Related Adverse Events from Immune Checkpoint Blockade
October 2021 | Volume 20 | Issue 10 | Features | 1133 | Copyright © October 2021
Immune checkpoint inhibitors (ICPis) have revolutionized outcomes in various advanced malignancies. Therapeutic restoration of a robust T-cell response against malignant cells is also at the root of d...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreA Comparison of Alternative Medicine Users and Non-Users in Patients With Hidradenitis Suppurativa
October 2021 | Volume 20 | Issue 10 | Original Article | 1072 | Copyright © October 2021
Background: Hidradenitis suppurativa patients often seek non-prescription therapies.
Objective: To determine the prevalence of alternative medicine use and char...
Read MoreIncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines
October 2021 | Volume 20 | Issue 10 | Original Article | 1052 | Copyright © October 2021
Background: To further explore clinical trial results indicating increasing doses of botulinum toxin A prolong duration of effect, a 2-stage, phase 2, randomized, double-blind study i...
Read MoreCharacteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database
October 2021 | Volume 20 | Issue 10 | Features | 1127 | Copyright © October 2021
Guselkumab is approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis. However, characteristics of patients initiating guselkumab in a real-world setting ...
Read MoreHolistic and Integrative Methods for Diagnosing and Treating the Underlying Causes of Inflammatory Skin Diseases
October 2021 | Volume 20 | Issue 10 | Features | 1121 | Copyright © October 2021
While the majority of patients are helped by current dermatologic therapy, there are a number of patients who find no relief, or are afraid of the side effects of powerful immunosuppressants that do n...
Read MoreSuccessful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab
October 2021 | Volume 20 | Issue 10 | Case Reports | 1113 | Copyright © October 2021
Brunsting-Perry is a rare variant of cicatricial pemphigoid, characterized by subepidermal bullae localized to the head and neck. Currently, treatment relies on non-specific immunosuppression, which i...
Read MoreSuccessful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report
October 2021 | Volume 20 | Issue 10 | Case Reports | 1117 | Copyright © October 2021
Palmoplantar pustulosis (PPP) is a rare, recurrent skin disorder that presents a major challenge to clinical therapy. We report a case of a 69-year-old woman with a 20-year history of psoriasis with s...
Read MoreSustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
August 2021 | Volume 20 | Issue 8 | Original Article | 880 | Copyright © August 2021
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoria...
Read MoreSerious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
August 2021 | Volume 20 | Issue 8 | Original Article | 855 | Copyright © August 2021
Background: Anti-interleukin (IL)-17 biologic agents used to treat psoriasis are associated with onset/exacerbation of inflammatory bowel disease (IBD). Objectives: To determine the incidence of IBD o...
Read MoreProceedings Report of the Fifth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2020
August 2021 | Volume 20 | Issue 8 | Original Article | 868 | Copyright © August 2021
The Symposium on Hidradenitis Suppurativa Advances (SHSA) is a joint meeting of the United States Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF)....
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 837 | Copyright © August 2021
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read MoreCalcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials
August 2021 | Volume 20 | Issue 8 | Original Article | 822 | Copyright © August 2021
Background: Psoriasis vulgaris is not easy to manage, even when mild. Knowledge of the efficacy of most topical therapies in this population is limited.
Objective:Read MoreSeeing the Treatment of Psoriasis in a New Light: A Novel Medical Device Utilizing Localized Coal Tar and Narrowband UVB for Targeted Treatment of Plaque Psoriasis
June 2021 | Volume 20 | Issue 6 | Features | 701 | Copyright © June 2021
Given the high costs of systemic psoriasis therapies, studies have also shown that phototherapy achieves significant cost savings by repla...
Read MoreFour-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)
April 2021 | Volume 20 | Issue 4 | Original Article | 436 | Copyright © April 2021
Background: Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid relief of symptoms followed by long-term managemen...
Read MoreEffect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies
April 2021 | Volume 20 | Issue 4 | Original Article | 394 | Copyright © April 2021
Objective: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque Read More
A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis
April 2021 | Volume 20 | Issue 4 | Original Article | 442 | Copyright © April 2021
Background: Biologic treatments have taken the forefront in treating moderate-to-severe psoria...
Read MoreHospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution
February 2021 | Volume 20 | Issue 2 | Original Article | 208 | Copyright © February 2021
Background: Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospit...
Read MoreDermatologists’ Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey
February 2021 | Volume 20 | Issue 2 | Original Article | 126 | Copyright © February 2021
Background: Psoriasis is commonly classified as either mild or moderate to severe, without specific parameters to differe...
Read More